TICKERNERD
Menu
NTLANTLAHealthcare · Biotechnology

NTLA Stock Forecast: Intellia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$11
+0.84% on the day

The 19 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $17 — +57.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
76 / 100
Median analyst target
$17
Analysts covering
19
Total return, dividends reinvested
1W
+0.9%
1M
−38.7%
YTD
+19.8%
1Y
−6.3%
From 52W high
−61.5%
From 52W low
+34.0%
$8
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Revisions
80
Accruals
75
Issuance
65
Momentum
57
Quality
42
Value
42
Size
40
Volatility
27

Growth (98): Sales and profits are climbing, and climbing faster than before.

Volatility (27): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

NTLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26NTLAHigh $95Median $17Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says19 analysts
9 Buy7 Hold3 Sell
Low $8Median $17High $95

The green dot is the last close — the median target sits +57.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 July 2026Wolfe ResearchDowngradeUnderperform$9.00
10 July 2026WedbushMaintainsNeutral$12 → $17
16 June 2026Canaccord GenuityMaintainsBuy—
15 June 2026CitizensReiteratesMarket Outperform—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026WedbushReiteratesNeutral—
13 May 2026BernsteinMaintainsMarket Perform—
13 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy—
12 May 2026WedbushReiteratesNeutral—
28 Apr 2026Canaccord GenuityMaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsSell—
28 Apr 2026Morgan StanleyMaintainsEqual-Weight—
27 Apr 2026BairdMaintainsNeutral—
27 Apr 2026Chardan CapitalMaintainsBuy—
4 Mar 2026Jones TradingUpgradeBuy—
3 Mar 2026Canaccord GenuityMaintainsBuy—
3 Mar 2026CitizensMaintainsMarket Outperform—
3 Mar 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NTLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
12
Analysts cutting
1
Fundamentals

Intellia Therapeutics, Inc. (NTLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 86% of US stocks

Price / sales
22.6×

Cheaper than 8% of US stocks

Price / book
2.1×

Cheaper than 45% of US stocks

EV / EBITDA
−2.9×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−9.5%

Higher than 16% of US stocks

Earnings growth (YoY)
−9.5%

Higher than 26% of US stocks

Gross margin
—
Operating margin
−668.1%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−56.3%

Higher than 20% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NTLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTLAIntellia Therapeutics, Inc.$1.5B
76
MAZEMaze Therapeutics, Inc.$1.5B
24
FBRXForte Biosciences, Inc.$1.5B
35
SLBTSL Science Holding Ltd.$1.5B
0
MLTXMoonLake Immunotherapeutics$1.5B
13
VIRVir Biotechnology, Inc.$1.5B
87
SEPNSepterna, Inc.$1.5B
84
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NTLA news & analysis

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 30 July 2026neutral

Intellia Therapeutics announced it will hold a conference call on August 6, 2026 at 8 a.m. ET to discuss its second quarter 2026 financial results and provide business updates.

Why it matters — NTLA watchers will be able to hear the company's latest financial performance and updates on its CRISPR gene-editing pipeline directly from management.

FAQ

Frequently asked questions about NTLA stock

What is the NTLA stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $8 to $95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTLA stock a buy right now?

Of the 19 analysts covering Intellia Therapeutics, Inc., 9 rate it a Buy, 7 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 76 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTLA?

As at 1 Aug 2026, Intellia Therapeutics, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will NTLA stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +57.8% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 76 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTLA stock forecast for 2030?

No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $95 over the next 12 months.

How has NTLA stock performed over the past year?

Intellia Therapeutics, Inc. returned -6.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform.

What is the latest news on NTLA?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates". Intellia Therapeutics announced it will hold a conference call on August 6, 2026 at 8 a.m. ET to discuss its second quarter 2026 financial results and provide business updates.

Company

About Intellia Therapeutics, Inc.

Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside the body in patient-derived cells (ex vivo). Its pipeline targets conditions with significant unmet medical need, including transthyretin (ATTR) amyloidosis, hereditary angioedema, sickle cell disease, and various immuno-oncology indications. Intellia Therapeutics Inc. collaborates with major pharmaceutical partners to advance and potentially scale its therapeutic programs, leveraging shared expertise in drug development and commercialization. Operating within the healthcare and biotechnology sector, the company plays a prominent role in the emerging field of gene editing, where its technologies are used to explore one-time, precisely targeted interventions for serious genetic disorders. Intellia Therapeutics Inc. is headquartered in Cambridge, Massachusetts, a key hub for life sciences and biotech innovation.

CEO Dr. John M. Leonard M.D. · 403 employees · United States · https://www.intelliatx.com